9144 POSTER EGFR Mutation Testing and First Line Treatment of Patients With Advanced NSCLC and Positive EGFR Mutation Status – Results From a German Registry

Eberhardt, W.; Thomas, Marc A.; Schulenburg, J.-Matthias Graf von der; Dietel, Manfred; Schirmacher, Peter; Gutendorf, Brigitte; Zirrgiebel, Ute; Schütte, W.

doi:10.1016/s0959-8049(11)72456-x

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the highest mean outpatient and inpatient costs were documented for chemotherapy patients. It should be noted that the AE profile of gefitinib in the REASON study was consistent with that described in the Summary of Product Characteristics [ 18 ]. At the end of the observation period, more patients in the TKI group did not have a nursing auxiliary listed compared with the chemotherapy group (62.6% vs. 51.6%).…”

Section: Discussionsupporting

confidence: 74%

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Schuette

Schirmacher

Eberhardt³

et al. 2018

BMC Cancer

View full text Add to dashboard Cite

BackgroundWe evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC).MethodsREASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secondary endpoints for EGFR Mut + NSCLC included progression-free survival (PFS), overall survival (OS), adverse event (AE) management, and pharmacoeconomic outcomes.ResultsAmong 334 patients with EGFR Mut + NSCLC, tyrosine kinase inhibitors (TKIs) were the most common first-line therapy (56.6%, 53.0% gefitinib). Among patients who received TKIs/gefitinib before first disease progression, PFS was longer compared with those who did not receive a TKI (median 10.1/10.0 vs. 7.0 months; HR 0.67/0.69; log-rank p = 0.012/p = 0.022). OS was longer for those patients who ever received a TKI/gefitinib during their complete therapy course compared with those who never received a TKI (median 18.4/18.1 vs. 13.6 months; HR 0.53/0.55; p = 0.003/p = 0.005). Total mean first-line treatment healthcare costs per person were higher for those receiving TKIs (€46,443) compared with those who received chemotherapy (€27,182). Mean outpatient and inpatient costs were highest with chemotherapy. Rash, diarrhea, and dry skin were the most commonly reported AEs for patients receiving gefitinib.ConclusionsIn REASON, TKI therapy was the most common first- and second-line treatment for EGFR Mut + NSCLC, associated with increased drug costs compared with chemotherapy. Patients who received gefitinib or a TKI ever during their complete therapy course had prolonged PFS and OS compared with patients who did not receive a TKI.Trial registrationThe trial was registered on October, 2009 with ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT00997230?term=NCT00997230&rank=1Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4032-3) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 74%

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Schuette

Schirmacher

Eberhardt³

et al. 2018

BMC Cancer

View full text Add to dashboard Cite

show abstract

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany

et al. 2015

View full text Add to dashboard Cite

show abstract

First- and Second-Line Treatment of Non-Small-Cell Lung Cancer Patients with EGFR Mutation-Positive Tumors

Reck

Reinmuth

Heigener

2012

Lung Cancer Manage.

View full text Add to dashboard Cite

SUMMARY EGFR is a mediator of cell proliferation and is targeted by EGFR tyrosine kinase inhibitors (TKIs) to treat non-small-cell lung cancer (NSCLC). Efficacy of EGFR TKIs (specifically erlotinib and gefitinib) is influenced by mutations in EGFR. We review the evidence for targeted use of EGFR TKIs in the first-line treatment of EGFR mutation-positive NSCLC, considering epidemiology and timing/methodology of diagnosis. First- and second-generation TKIs, and other investigational drugs, also have a role in the second-line treatment of EGFR mutation-positive NSCLC; we discuss this in the context of disease progression and drug resistance. Patients with EGFR mutation-positive tumors should be considered as a separate subpopulation within NSCLC, which is the first step towards individualized treatment of this disease.

show abstract

9144 POSTER EGFR Mutation Testing and First Line Treatment of Patients With Advanced NSCLC and Positive EGFR Mutation Status – Results From a German Registry

Cited by 4 publications

References 0 publications

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany

First- and Second-Line Treatment of Non-Small-Cell Lung Cancer Patients with EGFR Mutation-Positive Tumors

Contact Info

Product

Resources

About